Celltrion, Inc.
Biopharmaceutical firm developing biosimilars for autoimmune diseases and oncology.
068270 | KO
Overview
Corporate Details
- ISIN(s):
- KR7068270008
- LEI:
- Country:
- South Korea
- Address:
- 인천광역시 연수구 아카데미로 23, 인천광역시
- Website:
- https://www.celltrion.com/
- Sector:
- Manufacturing
Description
Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-04-01 00:00 |
투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 심사통과 (Part1))
|
Korean | 11.2 KB | ||
| 2025-03-25 00:00 |
정기주주총회결과
|
Korean | 19.8 KB | ||
| 2025-03-24 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-03-21 00:00 |
자기주식취득결과보고서
|
Korean | 32.1 KB | ||
| 2025-03-21 00:00 |
주요사항보고서(자기주식취득결정)
|
Korean | 33.5 KB | ||
| 2025-03-20 00:00 |
투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 한국 임상 3상 시험계획 신청)
|
Korean | 9.5 KB | ||
| 2025-03-18 00:00 |
기업가치제고계획(자율공시)
|
Korean | 8.8 KB | ||
| 2025-03-17 00:00 |
감사보고서제출
|
Korean | 19.6 KB | ||
| 2025-03-17 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 718.8 KB | ||
| 2025-03-17 00:00 |
사업보고서 (2024.12)
|
Korean | 5.9 MB | ||
| 2025-03-14 00:00 |
주식소각결정
|
Korean | 8.9 KB | ||
| 2025-03-12 00:00 |
의결권대리행사권유참고서류
|
Korean | 41.0 KB | ||
| 2025-03-12 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-03-12 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.9 KB | ||
| 2025-03-10 00:00 |
투자판단관련주요경영사항 (옴리클로(CTP39, 졸레어 바이오시밀러) 미국식품의약국(FDA) 최종 판매 허가 획득)
|
Korean | 8.9 KB |
Automate Your Workflow. Get a real-time feed of all Celltrion, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Celltrion, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celltrion, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
